The purpose of this study is to find a recommended dose level and schedule of dosing LY3023414 that can safely be taken by participants with advanced or metastatic cancer. The study will also explore the changes to various markers in blood cells and potentially tumor cells. Finally, the study will help document any antitumor activity this drug may have.
Key Participation Requirements
All clinical trials have rules about who can participate. This section outlines some of those rules. Please contact a study center to discuss the full set of criteria
Your participation could last up to 42 days or longer if you are tolerating the study drug and your study doctor thinks your condition is stable or improving.
Participant in Part B4 must have malignant pleural or peritoneal mesothelioma and appropriate candidate for treatment with cisplatin/pemetrexed; no prior systemic chemotherapy
Participant in Part B6 must have squamous NSCLC; documented evidence of an activating molecular aberration of the PI3K/mTOR pathway
Participant in Part B7 must have HR+ abd HER2- breast cancer
Participant may need to undergo a biopsy dependent upon which arm of the study you are in
Participant must not have known acute or chronic leukemia
Participant must be able to swallow capsules
Participant must be reliable and willing to make themselves available for the duration of the study and be willing to follow study procedures
Participant must not have insulin-dependent diabetes mellitus or a history of gestational diabetes mellitus
Advanced Cancer, Metastatic Cancer, Non-Hodgkin's Lymphoma, Metastatic Breast Cancer, Malignant Mesothelioma, Non-small Cell Lung Cancer
To improve your experience on Lilly TrialGuide, please use the latest version of Chrome, Firefox, Safari, or Internet Explorer, with Java Script enabled. This website is not optimized for your browser, as configured.